RECRUITING Phase 3 ClinicalTrials.gov

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Sponsor: Astellas Pharma Global Development, Inc. • ClinicalTrials.gov ID: NCT06901531

Registry updated: 2026-10-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive). Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. Certain stomach and GEJ cancers may be treated with immunotherapy, which helps the body's immune system fight cancer. This study will give more information about how well zolbetuximab works when given with an immunotherapy medicine called pembrolizumab and chemotherapy. In this study, adults with stomach cancer or GEJ cancer will either be given zolbetuximab with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. The main aim of the study is to check how long people with stomach cancer and GEJ cancer live after treatment with zolbetuximab with pembrolizumab and chemotherapy compared to placebo with pembrolizumab and chemotherapy. Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample (biopsy) of their cancer will have the Claudin 18.2 protein, PD-L1 protein, and be HER2-negative. They may have been previously treated with certain standard therapies. People can also take part if they need to take medicines like steroids to suppress their immune system. They cannot take part if they have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections. The study treatments are either zolbetuximab with pembrolizumab and chemotherapy, or placebo with pembrolizumab and chemotherapy. People who take part will receive just 1 of the study treatments by chance. The people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in 6-week (42-day) cycles. The study treatment is mainly given to people slowly through a tube into a vein. This is called an infusion. People will receive study treatment as follows: Zolbetuximab or placebo: 1 infusion every 2 or 3 weeks (2 or 3 infusions in a cycle) together with: Chemotherapy (1 of the following types of chemotherapy): 1. CAPOX (capecitabine and oxaliplatin): 1 infusion of oxaliplatin every 3 weeks (2 infusions in a cycle). People will also take 1 tablet of capecitabine twice a day for 2 weeks (14 days) at the start of each cycle (Day 1) and again in the middle of each cycle (Day 22). After 8 study treatments people will receive capecitabine only. 2. Modified FOLFOX6 or mFOLFOX6 (5-fluorouracil, folinic acid and oxaliplatin): 1 infusion every 2 weeks (3 infusions in a cycle). After 12 study treatments people will receive folinic acid and fluorouracil only, instead of mFOLFOX6. Pembrolizumab: 1 infusion every 3 or 6 weeks (1 or 2 infusions in a cycle). People can be in the study and will receive study treatment until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People may receive pembrolizumab for up to 2 years. People will visit the clinic on certain days to receive their study treatment and have health checks. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample if they stop treatment because their cancer has worsened. People will visit the clinic after they stop their study treatment. People will be asked about any medical problems and will have a health check. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. They will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.

Interventions

zolbetuximab (Drug)
Participants will receive an IV infusion of zolbetuximab on Cycle 1 Day 1 (C1D1) followed by subsequent IV infusion every 2 weeks or every 3 weeks.
Pembrolizumab (Drug)
Participants will receive an IV infusion of pembrolizumab every 3 weeks or every 6 weeks.
Capecitabine (Drug)
Participants receiving CAPOX regimen of chemotherapy will receive capecitabine Tablet twice daily orally on days 1 through 14 and days 22 through 35 of each cycle.
Oxaliplatin (Drug)
Participants receiving CAPOX or mFOLFOX6 regimen of chemotherapy will receive an IV infusion of oxaliplatin once every 2 or 3 weeks.
Folinic acid (leucovorin or local equivalent) (Drug)
Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of Folinic acid (leucovorin or local equivalent) once every 2 weeks.
5-fluorouracil (5-FU) (Drug)
Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion, or IV bolus of 5-FU once every 2 weeks.
Placebo (Drug)
Participants will receive an IV infusion of placebo (0.9% of sodium chloride) on C1D1 followed by subsequent IV infusion every 2 weeks or every 3 weeks.

Eligibility criteria

Inclusion Criteria: * Participant has histologically confirmed gastric or Gastroesophageal Junction (GEJ) adenocarcinoma. * Participant has radiographically confirmed, locally advanced, unresectable or metastatic disease within 28 days prior to randomization. * Participant has radiologically evaluable disease (measurable and/or nonmeasurable) according to Response Evaluation Criteria in Solid Tumors (RECIST) V1.1, ≤ 28 days prior to randomization. For participants with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy. * Participant has Eastern Cooperative Oncology Group Performance Status (ECOG) performance status 0 to 1. * Participant has predicted life expectancy ≥ 12 weeks. * Participant must be a candidate to receive mFOLFOX6 or CAPOX and pembrolizumab. * Female participant is not pregnant and at least 1 of the following conditions apply: * Not a woman of child bearing potential (WOCBP) * WOCBP who has a negative urine or serum pregnancy test at screening (Specific to Japan: with a medical interview), and agrees to follow the contraceptive guidance from the time of informed consent through at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study interventions. * Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study interventions). * Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period, and for 9 months after the final administration of oxaliplatin and for 6 months after final administration of all other study interventions. * Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period, and for 6 months after final investigational study intervention administration. * Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 6 months after the final investigational study intervention administration. * Male participant must not donate sperm during the treatment period and for 6 months after the final investigational study intervention administration * Participant has a Human Epidermal Growth Factor Receptor 2 (HER2) -negative tumor. * Participant's tumor expresses Claudin18.2 (CLDN18.2) in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing. * Participant's tumor expresses Programmed death ligand (PD-L1) combined positive score (CPS) ≥ 1 as determined by central IHC testing. * Participants with known microsatellite instability-high or mismatch repair deficient status may enroll as long as they meet the PD-L1 positivity criteria. * Participant must meet all of the criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In case of multiple central laboratory data within this period, the most recent data should be used. * Participant agrees not to participate in another interventional study while receiving study intervention in the present study. Exclusion Criteria: * Participant has prior severe allergic reaction or intolerance to zolbetuximab or other monoclonal antibodies, pembrolizumab, mFOLFOX6 or CAPOX. * Participant has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent recurrent vomiting. * Participant has significant gastric bleeding and/or untreated gastric ulcers that would preclude the participant from participation. * Participant has unresolved pneumonitis or history of non-infectious pneumonitis such as immune-related pneumonitis, radiation induced pneumonitis. * Participant has history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer. * Participant has a known history of a positive test for Human Immunodeficiency Virus (HIV) infection or known active Hepatitis B Surface Antigen (positive HBsAg) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements. * For participants who are negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, a hepatitis B DNA test will be performed and if positive the participant will be excluded. * Participants with positive Hepatitis C virus (HCV) serology, but negative HCV RNA test results are eligible. * Participants treated for HCV with undetectable viral load results are eligible. * Participant has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization. * Participant has active autoimmune disease that has required systemic treatment within the past 3 months prior to randomization. Participants with stable autoimmune disease who are receiving physiologic replacement doses of hydrocortisone or its equivalent are allowed. * Participant has a clinically significant disease or comorbidity that may adversely affect the safe delivery of treatment within this study or make the participant unsuitable for study participation. * Participant has another malignancy for which treatment is required. * Participant has known complete Dihydropyrimidine Dehydrogenase (DPD) deficiency (screening for DPD deficiency should be conducted per local requirements). * Participant has known peripheral neuropathy \> grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the participant ineligible). * Participant has sinusoidal obstruction syndrome, formerly known as veno-occlusive disease, if present, should be stable or improving. * Participant has significant cardiovascular disease, including any of the following: * Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization. * History of clinically significant ventricular arrhythmias (i.e., sustained; ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes). * QTc interval \> 450 msec for male participants; QTc interval \> 470 msec for female participants. * History or family history of congenital long QT syndrome. * Cardiac arrhythmias requiring anti-arrhythmic medications (participants with rate controlled atrial fibrillation for \> 1 month prior to randomization are eligible). * Participant has ongoing or previous interstitial lung disease, active diverticulitis or peptic ulcerative disease, or solid organ or stem cell transplant or other uncontrolled or clinically significant medical disorders. * Participant has type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy or skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed. * Participant has received prior systemic chemotherapy and/or immunotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, except for a maximum of 1 treatment course of mFOLFOX6 (day 1 to 14) or CAPOX (day 1 to 21) with or without pembrolizumab. However, participants may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as their disease progression occurred at least 6 months after the last dose. Participant who has received treatment with herbal medications that have known antitumor activity \> 28 days prior to randomization is allowed. * Participant has received systemic immunosuppressive therapy, including systemic corticosteroids 14 days prior to randomization. Participant using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single-dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use is allowed. * Participant has had major surgical procedure ≤ 28 days before randomization and has not completely recovered from the surgical procedure ≤ 14 days before randomization. * Participant has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has NOT recovered from any related toxicity. Palliative radiotherapy is allowed and must be completed \> 14 days prior to randomization. * Participant has received prior CLDN18.2 agents. * Participant received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. * Participant has received other investigational agents or devices concurrently or within 28 days prior to randomization or within 5 half-lives of the drug, whichever is longer. * Participant has any condition which makes the participant unsuitable for study participation. * Participant has any concurrent disease, infection, or co-morbid condition that interferes with the ability of the participant to participate in the study, which places the participant at undue risk or complicates the interpretation of data. * Treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to randomization or within 5 half-lives of the drug, whichever is shorter, is strictly prohibited. * Pernicious anemia or other anemias due to vitamin B12 deficiency. * Participant has a known history of a positive test for tuberculosis or known active tuberculosis infection. NOTE: Screening for these infections should be conducted per local requirements.

Conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer Metastatic Gastric Adenocarcinoma or Cancer Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Locations

UAB Medicine - UAB Hospital — Birmingham, Alabama, United States
CBCC Global Research - Comprehensive Blood & Cancer Center — Bakersfield, California, United States
TOI Clinical Research — Cerritos, California, United States
University of California, San Diego Moores Cancer Center — La Jolla, California, United States
The Angeles Clinic and Research Institute, West Los Angeles Office — Los Angeles, California, United States
Hartford HealthCare - Hartford Hospital — Hartford, Connecticut, United States
Yale University School of Medicine — New Haven, Connecticut, United States
MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States
Piedmont Physician Medical Oncology Atlanta — Atlanta, Georgia, United States
Northwestern Memorial Hospital — Chicago, Illinois, United States
Franciscan Health Oncology and Hematology Specialists — Indianapolis, Indiana, United States
Holden Comprehensive Cancer Center — Iowa City, Iowa, United States
University of Kansas Cancer Center — Westwood, Kansas, United States
Saint Elizabeth Medical Center Edgewood — Edgewood, Kentucky, United States
University of Maryland Medical System - University of Maryland Medical Center — Baltimore, Maryland, United States
Dana Farber/Harvard Cancer Center — Boston, Massachusetts, United States
University of Massachusetts - UMass Chan Medical School — Worcester, Massachusetts, United States
University of Michigan Health System — Ann Arbor, Michigan, United States
Barbara Ann Karmanos Cancer Center — Detroit, Michigan, United States
Henry Ford Cancer Institute-Henry Ford Hospital — Detroit, Michigan, United States
Metro Minnesota Community Oncology Research Consortium (MMCORC) — Saint Louis Park, Minnesota, United States
Oncology Hematology West PC dba Nebraska Cancer Specialists — Omaha, Nebraska, United States
University of Nebraska Medical Center — Omaha, Nebraska, United States
Capital Health - Hematology Oncology Specialists — Pennington, New Jersey, United States
NYU Langone Medical Center — New York, New York, United States
Montefiore Medical Center — The Bronx, New York, United States
University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
Duke University Medical Center - Duke Cancer Centre — Durham, North Carolina, United States
Allegheny General Hospital (AGH)-Allegheny Singer Research Institute — Pittsburgh, Pennsylvania, United States
Rhode Island Hospital — Providence, Rhode Island, United States
The University of Tennessee Medical Center — Knoxville, Tennessee, United States
Vanderbilt University Medical Center — Nashville, Tennessee, United States
Texas Oncology-Baylor Charles A Sammons Cancer Center — Dallas, Texas, United States
The Center For Cancer And Blood Disorders (Texas Cancer Care) — Fort Worth, Texas, United States
Houston Methodist Cancer Center — Houston, Texas, United States
Utah Cancer Specialists Cancer Center - Medical Oncology — Salt Lake City, Utah, United States
Inova Schar Cancer Institute Clinical Trials — Fairfax, Virginia, United States
Site AU61002 — Kogarah, New South Wales, Australia
Site AU61004 — Brisbane, Queensland, Australia
Site AU61003 — Clayton, Victoria, Australia
Site AU61001 — Fitzroy, Australia
Site BE32002 — Bonheiden, Belgium
Site BE32001 — Brussels, Belgium
Site BE32006 — Edegem, Belgium
Site BE32003 — Ghent, Belgium
Site BE32005 — Leuven, Belgium
Site BE32004 — Liège, Belgium
Site BR55014 — Belo Horizonte, Brazil
Site BR55002 — Blumenau, Brazil
Site BR55012 — Fortaleza, Brazil
Site BR55008 — Jaú, Brazil
Site BR55004 — Lages, Brazil
Site BR55003 — Porto Alegre, Brazil
Site BR55006 — São Caetano do Sul, Brazil
Site BR55001 — São José do Rio Preto, Brazil
BR55009 — São Paulo, Brazil
BR55010 — São Paulo, Brazil
Site BR55007 — São Paulo, Brazil
Site BR55011 — São Paulo, Brazil
Site CL56004 — Las Condes, Chile
Site CL56001 — Santiago, Chile
Anhui Provincial Cancer Hospital — Hefei, Anhui, China
Fujian Provincial Hospital - Department of Medical Oncology — Fuzhou, Fujian, China
Sun Yat-sen University - Cancer Center — Guangzhou, Guangdong, China
Sun Yat-sen University - Cancer Center — Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital - Oncology — Harbin, Heilongjiang, China
Henan Cancer Hospital - Oncology — Zhenngzhou, Henan, China
Hubei Cancer Hospital - Oncology — Wuhan, Hubei, China
Qinghai University Affiliated Hospital — Xining, Qinghai, China
Renji Hospital Shanghai Jiaotong Univ School of Medicine — Shanghai, Shanghai Municipality, China
Ruijin Hospital of Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality, China
Sichuan Cancer Hospital — Chengdu, Sichuan, China
Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China
Affiliated Hospital of Hebei University — Baoding, China
Peking Union Medical College Hospital - Dongdan Campus — Beijing, China
Site CZ42006 — Brno, Czechia
Site CZ42005 — Olomouc, Czechia
Site CZ42002 — Prague, Czechia
Site CZ42003 — Prague, Czechia
Site CZ42004 — Prague, Czechia
Site FR33016 — Bordeaux, France
Site FR33008 — Brest, France
Site FR33012 — Caen, France
Site FR33009 — Carassonne, France
Site FR33005 — Dijon, France
Site FR33002 — Lille, France
Site FR33007 — Lille, France
Site FR33014 — Lyon, France
Site FR33017 — Lyon, France
Site FR33020 — Montpellier, France
Site FR33018 — Nice, France
Site FR33003 — Paris, France
Site FR33010 — Paris, France
Site FR33013 — Paris, France
Site FR33015 — Plérin, France
Site FR33004 — Poitiers, France
Site FR33006 — Rouen, France
Site FR33019 — Saint Herbian Cedex, France
Site FR33011 — Strasbourg, France
Site DE49013 — Berlin, Germany
Site DE49010 — Essen, Germany
Site DE49017 — Frankfurt am Main, Germany
Site DE49007 — Hanover, Germany
Site DE49004 — Leipzig, Germany
Site DE49001 — Mainz, Germany
Site DE49014 — Munich, Germany
Site DE49006 — Nuremberg, Germany
Site DE49002 — Saarbrücken, Germany
Site DE49011 — Schweinfurt, Germany
Site DE49016 — Wolfsburg, Germany
Site IT39003 — Ancona, Italy
Site IT39019 — Bergamo, Italy
Site IT39017 — Bologna, Italy
Site IT39009 — Brescia, Italy
Site IT39014 — Candiolo, Italy
Site IT39006 — Cremona, Italy
Site IT39011 — Florence, Italy
Site IT39007 — Meldola, Italy
Site IT39012 — Milan, Italy
Site IT39018 — Milan, Italy
Site IT39020 — Milan, Italy
Site IT39021 — Naples, Italy
Site IT39015 — Pisa, Italy
Site IT39004 — Reggio Emilia, Italy
Site IT39016 — Roma, Italy
Site IT39001 — Rome, Italy
Site IT39022 — Udine, Italy
Site IT39002 — Verona, Italy
Chiba Cancer Center — Chiba, Chiba, Japan
National Cancer Center Hospital East — Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center — Matsuyama, Ehime, Japan
Kyushu University Hospital (Hematology, Oncology & Cardiovascular medicine) — Fukuoka, Fukuoka, Japan
Kyushu University Hospital(Gastrointestinal Surgery) — Fukuoka, Fukuoka, Japan
National Hospital Organization Kyushu Cancer Center — Fukuoka, Fukuoka, Japan
Gunma University Hospital — Maebashi, Gunma, Japan
Hokkaido University Hospital — Sapporo, Hokkaido, Japan
Hyogo Cancer Center — Akashi-shi, Hyōgo, Japan
Kobe City Medical Center General Hospital — Kobe, Hyōgo, Japan
Kagawa University Hospital — Kida-gun, Kagawa-ken, Japan
St. Marianna University Hospital — Kawasaki-shi, Kanagawa, Japan
Kanagawa Cancer Ctr Hospital — Yokohama, Kanagawa, Japan
Tohoku University Hospital — Sendai, Miyagi, Japan
Osaka General Medical Center — Osaka, Osaka, Japan
Osaka International Cancer Institute — Osaka, Osaka, Japan
Osaka University Hospital — Suita-shi, Osaka, Japan
Saitama Medical University International Medical Center — Hidaka-shi, Saitama, Japan
Saitama Cancer Center — Kitaadachi-gun Ina-machi, Saitama, Japan
Shizuoka Cancer Center — Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital — Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of JFCR — Koto-ku, Tokyo, Japan
Site LT37001 — Kaunas, Lithuania
Site LT37002 — Vilnius, Lithuania
Site MX52003 — Mexico City, Mexico
Site MX52001 — Oaxaca City, Mexico
Site NL31002 — Leeuwarden, Netherlands
Site NL31001 — Nijmegen, Netherlands
Site PL48005 — Lubin, Lubusz Voivodeship, Poland
Site PL48004 — Warsaw, Masovian Voivodeship, Poland
Site PL48001 — Brzozów, Woj Podkarpackie, Poland
Site PL48006 — Gliwice, Poland
Site PL48008 — Olsztyn, Poland
Site PL48002 — Przemyśl, Poland
Site PL48009 — Swidnica, Poland
Site PL48007 — Warsaw, Poland
Site PT35106 — Almada, Portugal
Site PT35103 — Braga, Portugal
Site PT35104 — Guimarães, Portugal
Site PT35102 — Lisbon, Portugal
Site PT35107 — Lisbon, Portugal
Site PT35105 — Porto, Portugal
Site PT35108 — Porto, Portugal
Site PT35109 — Porto, Portugal
Site RO40008 — Bucharest, Romania
Site RO40001 — Cluj-Napoca, Romania
Site RO40005 — Cluj-Napoca, Romania
Site RO40006 — Cluj-Napoca, Romania
Site RO40003 — Craiova, Romania
Site RO40002 — Floreşti, Romania
Site RO40007 — Iași, Romania
Site RO40004 — Timișoara, Romania
Site KR82011 — Goyang-si, Gyeonggi-do, South Korea
Site KR82007 — Seongnam-si, Gyeonggi-do, South Korea
Site KR82013 — Suwon, Gyeonggi-do, South Korea
Site KR82015 — Suwon, Gyeonggi-do, South Korea
Site KR82014 — Hwasungun, Joellanamdo, South Korea
Site KR82009 — Cheongju-si, North Chungcheong, South Korea
Site KR82003 — Seocho-gu, Seoul, South Korea
Site KR82004 — Daegu, South Korea
Site KR82005 — Incheon, South Korea
Site KR82001 — Seoul, South Korea
Site KR82002 — Seoul, South Korea
Site KR82006 — Seoul, South Korea
Site KR82008 — Seoul, South Korea
Site KR82010 — Seoul, South Korea
Site KR82012 — Seoul, South Korea
Site ES34022 — Elche, Alicante, Spain
Site ES34023 — San Cugat Del Valles Barcelona, Cataluyna, Spain
Site ES34019 — Madrid, Madrid, Spain
Site ES34027 — Madrid, Madrid, Spain
Site ES34002 — Navarra, Pamplona, Spain
Site ES34005 — A Coruña, Spain
Site ES34006 — Barcelona, Spain
Site ES34009 — Barcelona, Spain
Site ES34010 — Barcelona, Spain
Site ES34011 — Barcelona, Spain
Site ES34024 — Barcelona, Spain
Site ES34026 — Barcelona, Spain
Site ES34028 — Barcelona, Spain
Site ES34021 — El Palmar, Spain
Site ES34014 — Lleida, Spain
Site ES34003 — Madrid, Spain
Site ES34008 — Madrid, Spain
Site ES34016 — Madrid, Spain
Site ES34017 — Madrid, Spain
Site ES34031 — Madrid, Spain
Site ES34030 — Murcia, Spain
Site ES34013 — Pozuelo de Alarcón, Spain
Site ES34029 — Santiago de Compostela, Spain
Site ES34012 — Seville, Spain
Site ES34025 — Seville, Spain
Site ES34004 — Valencia, Spain
Site ES34007 — Valencia, Spain
Site ES34015 — Zaragoza, Spain
Site ES34018 — Zaragoza, Spain
Site TW88603 — Dawan, Taiwan, Taiwan
Site TW88604 — Kaohsiung City, Taiwan
Site TW88601 — Taichung, Taiwan
Site TW88606 — Tainan, Taiwan
Site TW88605 — Taipei, Taiwan
Site TR90011 — Adana, Turkey (Türkiye)
Site TR90001 — Ankara, Turkey (Türkiye)
Site TR90004 — Ankara, Turkey (Türkiye)
Site TR90006 — Ankara, Turkey (Türkiye)
Site TR90014 — Bursa, Turkey (Türkiye)
Site TR90005 — Istanbul, Turkey (Türkiye)
Site TR90013 — Konya, Turkey (Türkiye)
Site TR90009 — Samsun, Turkey (Türkiye)
Site TR90015 — Van, Turkey (Türkiye)
Site GB44010 — Cottingham, East Riding Of Yorkshire, United Kingdom
Site UK44001 — Bristol, United Kingdom
Site GB44003 — Cardiff, United Kingdom
Site GB44002 — Coventry, United Kingdom
Site UK44006 — Dundee, United Kingdom
Site GB44004 — Glasgow, United Kingdom
Site GB44005 — London, United Kingdom
Site UK44011 — London, United Kingdom
Site UK44014 — London, United Kingdom
Site UK44015 — London, United Kingdom
Site UK44016 — London, United Kingdom
Site UK44009 — Manchester, United Kingdom
Site GB44008 — Sheffield, United Kingdom

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment